The European Journal of Health Economics
Costs and use of antimigraine drugs in Italy: a ten-year analysis of national data
Abstract Background Migraine is a highly prevalent neurological disorder associated with substantial disability and economic burden. Considering the recent introduction of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), expenditure analysis are needed to evaluate a rapidly evolving therapeutic field. Therefore, we analyzed national pharmaco-utilization trends of antimigraine drugs in Italy over the decade 2014–2023 using publicly available data from the “ Osservatorio Nazionale sull’Impieg …